$4.58
0.00%
Nasdaq, Thu, Jul 03 2025
ISIN
US6412557083
Symbol
NURO

NeuroMetrix, Inc. Stock price

$4.58
+0.00 0.00% 1M
+0.65 16.66% 6M
+0.61 15.37% YTD
+0.85 22.82% 1Y
-24.54 84.27% 3Y
-12.30 72.87% 5Y
-2,448.67 99.81% 10Y
-1,869,000.22 100.00% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+0.00 0.00%
ISIN
US6412557083
Symbol
NURO
Sector

Key metrics

Basic
Market capitalization
$9.4m
Enterprise Value
$-3.7m
Net debt
positive
Cash
$13.1m
Shares outstanding
2.1m
Valuation (TTM | estimate)
P/E
negative | -
P/S
3.1 | -
EV/Sales
negative | -
EV/FCF
0.5
P/B
0.7
Financial Health
Equity Ratio
93.4%
Return on Equity
-54.5%
ROCE
-61.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.0m | -
EBITDA
$-8.7m | -
EBIT
$-8.8m | -
Net Income
$-7.8m | -
Free Cash Flow
$-7.1m
Growth (TTM | estimate)
Revenue
-48.6% | -
EBITDA
-22.6% | -
EBIT
-22.9%
Net Income
-19.6% | -
Free Cash Flow
-13.7%
Margin (TTM | estimate)
Gross
55.4%
EBITDA
-286.5% | -
EBIT
-289.6%
Net
-257.4% | -
Free Cash Flow
-235.0%
More
EPS
$-3.8
FCF per Share
$-3.5
Short interest
0.1%
Employees
13
Rev per Employee
$230.0k
Show more

Is NeuroMetrix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

NeuroMetrix, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a NeuroMetrix, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a NeuroMetrix, Inc. forecast:

Buy
86%
Hold
14%

Financial data from NeuroMetrix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3.03 3.03
49% 49%
100%
- Direct Costs 1.35 1.35
31% 31%
45%
1.68 1.68
57% 57%
55%
- Selling and Administrative Expenses 8.67 8.67
4% 4%
286%
- Research and Development Expense 1.79 1.79
35% 35%
59%
-8.69 -8.69
23% 23%
-287%
- Depreciation and Amortization 0.09 0.09
50% 50%
3%
EBIT (Operating Income) EBIT -8.78 -8.78
23% 23%
-290%
Net Profit -7.81 -7.81
20% 20%
-258%

In millions USD.

Don't miss a Thing! We will send you all news about NeuroMetrix, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroMetrix, Inc. Stock News

Neutral
Business Wire
6 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NeuroMetrix, Inc. (NasdaqCM: NURO) to electroCore, Inc. Under the terms of the proposed transaction, shareholders of NeuroMetrix will receive one non-tradeable contingent value right (the “CVR”) per share of NURO ...

Company Profile

NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables. It offers an over-the-counter wearable therapeutic device for chronic pain, the Quell Health Cloud, DPNCheck, and pain management devices to treat chronic pain, nerve diseases, and sleep disorder. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Head office United States
CEO Daniel Goldberger
Employees 13
Founded 1996
Website www.neurometrix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today